

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 784 050 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
16.07.1997 Bulletin 1997/29

(51) Int. Cl.<sup>6</sup>: C07C 237/08, A23L 1/236

(21) Application number: 96120524.2

(22) Date of filing: 19.12.1996

(84) Designated Contracting States:  
BE CH DE FR GB IT LI NL

(30) Priority: 12.01.1996 JP 3651/96  
01.04.1996 JP 78718/96  
01.11.1996 JP 291501/96

(71) Applicant: Ajinomoto Co., Inc.  
Tokyo 104 (JP)

(72) Inventors:  
• Takemoto, Tadashi,  
Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

• Amino, Yusuke,  
Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)  
• Nakamura, Ryolchiro,  
Ajinomoto Co., Inc.  
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

(74) Representative: Strehl Schübel-Hopf Groening &  
Partner  
Maximilianstrasse 54  
80538 München (DE)

### (54) Novel aspartylamide derivatives and sweeteners

(57) A low-calory sweetener which exhibits a high level of stability, an excellent safety and an excellent sweetness is provided. The object of the present invention is accomplished by the provision of novel aspartylamide derivatives such as N- $\alpha$ -L-aspartyl-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide, N- $\alpha$ -L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide) and the like, and a sweetener containing the above-mentioned derivatives or salts thereof as an active ingredient.

EP 0 784 050 A1

**Description****Field of the Invention**

5 The present invention relates to novel aspartylamide derivatives and salts thereof as well as a sweetener containing the same as an active ingredient.

**Background of the Invention**


10 In recent years, eating habits have been improved to a high level, and fatness caused by excessive intake of sugar and diseases accompanied by the fatness have been at issue. Therefore, the development of a low-calory sweetener that replaces sugar has been in demand. As a sweetener that has been widely used at present, there is aspartame which is excellent in terms of a safety and sweetness properties. However, it involves a problem of a stability. In order to improve the stability and the sweetness intensity, an aspartylamide derivative which is a condensate of aspartic acid  
 15 and  $\beta$ -amino-alcohol and which is free from an ester linkage was studied. Thus, the compounds described in U. S. Patent No. 4,423,029, European Patent No. EP 0203540A1, J. Med. Chem., 13, 1217 (1970) or Tetrahedron Letters, 35, 6891 (1994) were found. Meanwhile, it is described in French Patent No. 2,697,844 that aspartylpeptide derivatives in which an alkyl group has been introduced into an amino group exhibits an extremely increased degree of sweetness. However, these compounds do not satisfy the stability.

**Problems To Be Solved by the Invention**

20 The present invention is to provide novel aspartylamide derivatives and salts thereof which are obtained by using an easily-obtainable amino-alcohol component and which exhibit a high level of safety and an excellent stability, as well  
 25 as a low-calory sweetener containing the same as an active ingredient.

**Means Taken For Solving the Problems**

30 In order to solve the above-mentioned problems, the present inventors have assiduously conducted investigations with respect to an N-alkyl group and an amino-alcohol component of aspartylamide derivatives, and have consequently found that aspartylamide derivatives represented by the following formula (I) are used as a sweetener which is excellent in terms of sweetness intensity, stability and sweetness properties. This finding has led to the completion of the present invention.




wherein

40  $R_1$  represents H, a saturated or unsaturated linear or cyclic hydrocarbon group having from 1 to 13 carbon atoms, or a mixed hydrocarbon group thereof;

45  $R_2$  and  $R_3$  each represent H, or a substituent selected from an alkyl group having from 1 to 6 carbon atoms, an alkoxyalkyl group having from 2 to 7 carbon atoms, a hydroxyalkyl group having from 2 to 7 carbon atoms, a phenyl group, a 2-furyl group, a dimethylene group, a trimethylene group, a tetramethylene group and a pentamethylene group;

50 when  $R_1$  is a saturated or unsaturated linear or cyclic hydrocarbon group having from 1 to 13 carbon atoms or a mixed hydrocarbon group thereof,  $R_4$  represents an alkyl group having from 1 to 12 carbon atoms, or a substituent represented by formula (II) or (III), and when  $R_1$  is H,  $R_4$  represents a substituent represented by formula (III)



in which

in formula (II)

$R_5$  represents H, or an alkyl group having from 1 to 4 carbon atoms,

$R_6$  represents a 3- to 10-membered cycloalkyl group having a total of 12 or less carbon atoms, a cycloalkenyl group, a cycloalkyl group which is substituted by an alkyl group, a cycloalkenyl group, a bicycloalkyl group, a bicycloalkenyl group, or a tricycloalkenyl group, and

$n$  represents 0 or 1, and

in formula (III)

R<sub>7</sub> and R<sub>8</sub> each represent H, a cycloalkyl group having from 3 to 4 carbon atoms, an alkyl group having from 1 to 6 carbon atoms, an alkoxyalkyl group having from 2 to 7 carbon atoms, a phenyl group, a phenyl group having a substituent selected from F, Cl, Br, I, a hydroxy group, an alkyl group having from 1 to 6 carbon atoms, an alkoxy group having from 2 to 7 carbon atoms, a cyano group, a nitro group, an acetyl group, an amino group and an acetylamino group in the 2-, 3- or 4-position, a phenyl group having a methylenedioxy group, a trimethylene group or a tetramethylene group in the 2-and 3-positions or in the 3- and 4-positions, a 2-, 3- or 4-pyridyl group, a 2- or 3-furyl group, or a 2- or 3-thienyl group, and

m represents 0 or 1; and

the C<sup>1</sup>-configuration is (S), and the C<sup>2</sup>-, C<sup>3</sup>- and C<sup>4</sup>-configurations are (R), (S) or (RS).

#### Mode of Carrying Out the Invention

The novel aspartylamide derivatives of the present invention are the compounds of formula (I) and salts thereof.

Examples of the salts of the compounds in the present invention include salts with alkali metals such as sodium and potassium; salts with alkaline-earth metals such as calcium and magnesium; salts with amines such as monoethanolamine; salts with inorganic acids such as hydrochloric acid and sulfuric acid; and salts with organic acids such as citric acid and acetic acid.

The aspartylamide derivatives of the present invention can be formed by a usual peptide synthesis method (Izumiya et al., Basis of Peptide Synthesis and Experiments thereof, Maruzen, January 20, 1985). That is, desired  $\alpha$ -L-aspartylamide can be formed by first condensing an amino-alcohol with L-aspartic acid in which the carboxylic acid in the  $\beta$ -position and the amino group are protected to obtain an amide, and then removing the protective groups, or by first converting L-aspartic acid in which the carboxylic acid in the  $\beta$ -position and the amino group are protected into an active ester, reacting this ester with an amino-alcohol to obtain an amide, and then removing the protective groups.

However, the method of forming the compounds in the present invention is not limited thereto.

The N-alkylaspartylamide derivatives can be formed by obtaining an amide of L-aspartic acid having protective groups and an amino-alcohol, then selectively removing the N-protective group, reductively alkylating the resulting compound with an aldehyde [A. F. Abdel-Magid et al., Tetrahedron Letters, 31, 5595 (1990)], and further removing the remaining protective group. That is, an amino-alcohol is first condensed with L-aspartic acid in which the carboxylic acid in the  $\beta$ -position and the amino group are protected to obtain an amide, or L-aspartic acid in which the carboxylic acid in the  $\beta$ -position and the amino group are protected is first converted into an active ester, and this active ester is then reacted with an amino-alcohol to obtain an amide. The N-protective group of this protected aspartylamide is selectively removed, the resulting substance is reductively alkylated with an aldehyde and a reducing agent [for example, NaB(OAc)<sub>3</sub>H], and the remaining protective group is then removed to give a desired N-alkyl- $\alpha$ -L-aspartylamide. The N-alkyl- $\alpha$ -L-aspartylamide can also be obtained by reductively alkylating the above-obtained  $\alpha$ -L-aspartylamide with an aldehyde and a reducing agent (for example, palladium on carbon). However, the method of forming the compounds of the present invention is not limited thereto. The amino-alcohol which is used to produce the compounds of the present invention can easily be obtained from an amino acid as an optically active substance by the method described in the literature [Tetrahedron Letters, by M. W. Holladay et al., 24, 4401 (1983), or Angew. Chem. Int. Ed. Engl., by M. T. Reets et al., 26, 1141 (1987)]. However, the method of forming the amino-alcohol in the present invention is not limited thereto.

As a result of the sensory evaluation, it was found that the compounds of the present invention and the salts thereof have a strong sweetness and their sweetness qualities are similar to that of sugar. For example, the degree of sweetness of N- $\alpha$ -L-aspartyl-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide was approximately 2,500 times (that of sugar), the degree of sweetness of N- $\alpha$ -L-aspartyl-(1R, 2S, 4R)-1-methyl-2-hydroxy-4-phenylhexylamide was approximately 1,500 times (that of sugar), the degree of sweetness of N- $\alpha$ -L-aspartyl-(1R, 2S, 4RS)-1-methyl-2-hydroxy-4-phenylhexylamide was approximately 2,300 times (that of sugar), the degree of sweetness of N- $\alpha$ -L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide was approximately 5,500 times (that of sugar), the degree of sweetness of N- $\alpha$ -L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2S, 4R)-1-methyl-2-hydroxy-4-phenylhexylamide was approximately 3,000 times (that of sugar), the degree of sweetness of N- $\alpha$ -L-(N'-2-ethylbutylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide was approximately 3,000 times (that of sugar), and the degree of sweetness of N- $\alpha$ -L-(N'-3-methylbutylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide was approximately 4,000 times (that of sugar).

The half-life (in a phosphate buffer of pH 3 at 70°C) of N- $\alpha$ -L-aspartyl-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide in an acidic aqueous solution was approximately 289 hours, and it was by far stabler than aspartame (half-life approximately 24 hours).

Further, N- $\alpha$ -L-aspartyl-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide was subjected to a toxicity test in one oral administration (2.0 g/kg) using ICR-strain mice. Consequently, it was found that this compound has no problem with respect to the safety.

The structures of the aspartylamide derivatives formed and the results of the sensory evaluation thereof are shown in Table 1.



(I)

Table 1

Structures of aspartylamide derivatives and degrees of sweetness thereof							
	$R_1$	$R_2$	$R_3$	$C^2$ -con- figuration	$C^3$ -config- uration S:R	$R_4$	Degree of sweetness <sup>1)</sup>
15	H	H	Me	R	>5:1	(S)-2-phenylbutyl	2500
	H	H	Me	R	>9:1	(R)-2-phenylbutyl	1500
	H	H	Me	R	>9:1	(RS)-2-phenylbutyl	2300
20	H	H	Me	R	3:7	(RS)-2-phenylbutyl	1000
	H	H	Me	R	3:7	(R)-2-phenylbutyl	800
	H	H	Me	R	7:3	(RS)-2-phenylpropyl	700
25	H	H	Me	R	7:3	(RS)-2-phenyl-3-meth- oxypropyl	100
	H	H	Et	R	>9:1	(RS)-2-phenylbutyl	250
	H	H	MeCH-(OH)	R	9:1	(RS)-2-phenylbutyl	100
30	H	Me	Me	-	1:1	(RS)-2-phenylbutyl	250
	H	H	Me	R	9:1	(2)-phenylethyl	50
	3,3-dimethylbutyl	H	Me	R	>5:1	(S)-2-phenylbutyl	5500
35	3,3-dimethylbutyl	H	Me	R	>9:1	(R)-2-phenylbutyl	3000
	2-ethylbutyl	H	Me	R	>5:1	(S)-2-phenyl butyl	3000
	3-methylbutyl	H	Me	R	>5:1	(S)-2-phenylbutyl	4000
40	3,3-dimethylbutyl	H	Me	R	>9:1	cyclohexylmethyl	100
	3,3-dimethylbutyl	H	Me	R	3:7	cyclohexylmethyl	750

1) Relative to a degree of sweetness of a 4-% sucrose aqueous solution.

2) The  $C^1$ -configuration is (S).

When the compounds of the present invention or the salts thereof are used as a sweetener, these compounds may be used in combination with other sweeteners unless inviting any troubles.

#### Example 1

##### Synthesis of N- $\alpha$ -L-aspartyl-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide

50 LAH (0.73 g, 19.25 mmols) was suspended in 50 ml of ether, and the suspension was maintained at 0°C. To this suspension were added 3.44 g (11.0 mmols) of N-methoxy-N-methylcarboxamide of N,N-dibenzyl- $\alpha$ -D-alanine. The mixture was stirred at 0°C for 1 hour, and 50 ml of a 1-M potassium hydrogensulfate aqueous solution were added thereto. The reaction solution was extracted twice with 50 ml of ether. The organic layer was washed with 50 ml of a 5-55 % sodium hydrogencarbonate aqueous solution and with a saturated aqueous solution of sodium chloride, and was dried over anhydrous magnesium sulfate. Magnesium sulfate was removed by filtration, and the filtrate was concentrated to obtain 2.76 g (10.9 mmols) of (R)-2-N,N-dibenzylaminopropyl aldehyde.

Magnesium (0.24 g, 9.9 mmols) was suspended in 1 ml of THF, and a solution of 1.41 g (6.6 mmols) of (R)-2-phenylbutyl bromide in 2 ml of THF was added dropwise to the suspension. The reaction solution was stirred at room tem-

perature for 1 hour, and 5 ml of THF were added thereto. The mixed solution was cooled to 0°C. To the reaction solution was added a solution obtained by dissolving 1.37 g (5.5 mmols) of the above-obtained (R)-2-N,N-dibenzylaminopropyl aldehyde in 10 ml of THF, and the mixture was stirred at 0°C for 1 hour. To this reaction solution were added 50 ml of a saturated aqueous solution of ammonium chloride, and the mixture was extracted twice with 50 ml of ether. The organic layer was washed with 5-% sodium hydrogencarbonate and with a saturated aqueous solution of sodium chloride, and was dried over anhydrous magnesium sulfate. Magnesium sulfate was removed by filtration, and the filtrate was concentrated. The residue was purified by PTLC to give 1.46 g (3.77 mmols) of N,N-dibenzyl-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamine (2S:2R = >5:1).

N,N-dibenzyl-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamine (1.46 g, 3.77 mmols) was dissolved in 25 ml of methanol, and 0.43 ml (7.53 mmols) of acetic acid and 0.6 g of 5-% palladium on carbon (water content 50%) were added thereto. The reaction solution was stirred under a hydrogen atmosphere at 50°C for 16 hours. Subsequently, the catalyst was removed by filtration, and the filtrate was concentrated. To the residue were added 15 ml of a saturated aqueous solution of sodium hydrogencarbonate, and the mixture was extracted twice with 50 ml of methylene chloride. The organic layer was dried over anhydrous magnesium sulfate, and magnesium sulfate was then removed by filtration. The filtrate was concentrated to obtain 0.61 g (2.96 mmols) of (1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamine.

To 30 ml of methylene chloride were added 1.17 g (3.26 mmols) of N-benzyloxycarbonyl-L-aspartic acid-β-benzyl ester and 0.61 g (2.96 mmols) of (1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamine. The reaction solution was cooled to 0°C, and 0.63 g (3.26 mmols) of water-soluble carbodiimide hydrochloride and 0.44 g (3.26 mmols) of HOBT were added thereto. The mixture was stirred for 1 hour while being cooled and then overnight at room temperature. After the reaction mixture was concentrated under reduced pressure, 50 ml of water were added to the residue, and the mixture was extracted twice with 50 ml of ethyl acetate. The organic layer was washed twice with a 5-% citric acid aqueous solution, with 50 ml of water, twice with 50 ml of a 5-% sodium hydrogencarbonate aqueous solution and with 50 ml of a saturated aqueous solution of sodium chloride. After the organic layer was dried over anhydrous magnesium sulfate, magnesium sulfate was removed by filtration. The filtrate was concentrated under reduced pressure, and was purified with PTLC to obtain N-α-L-(N'-benzyloxycarbonyl-β-O-benzylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide as a viscous oil.

N-α-L-(N'-benzyloxycarbonyl-β-O-benzylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide (1.32 g, 2.42 mmols) was dissolved in 40 ml of methanol, and 5 ml of water and 0.85 g of 5-% palladium on carbon (water content 50%) were added thereto. The mixed solution was reduced under a hydrogen atmosphere overnight at room temperature. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was then dried to give 0.72 g (2.23 mmols) of N-α-L-aspartyl-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide (2S:2R = 5:1).

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>) δ:0.67(t,3H), 0.99(d,3H), 1.38-1.60(m,2H), 1.63-1.76(m,2H), 2.53-2.65(m,1H), 2.60-2.80(2dd,2H), 3.49(m,1H), 3.74(m,1H), 3.94(t,1H), 7.14-7.31(m,5H),

35 8.32(d,1H)

ESI-MS 323.2 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 2,500 times

#### Example 2

#### Synthesis of N-α-L-aspartyl-(1R, 2S, 4R)-1-methyl-2-hydroxy-4-phenylhexylamide

Example 1 was repeated except that (S)-2-phenylbutyl bromide was used instead of (R)-2-phenylbutyl bromide to give N-α-L-aspartyl-(1R, 2S, 4R)-1-methyl-2-hydroxy-4-phenylhexylamide (2S:2R = >9:1) as a solid in a total yield of 54.2%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>) δ:0.69(t,3H), 0.93(d,3H), 1.45-1.68(m,4H), 2.64-2.77(m,3H), 3.10(m,1H), 3.57(m,1H), 3.94(t,1H), 7.14-7.31(m,5H), 8.28(d,1H)

ESI-MS 322.9 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 1,500 times

#### Example 3

#### Synthesis of N-α-L-aspartyl-(1R, 2S, 4RS)-1-methyl-2-hydroxy-4-phenylhexylamide

Example 1 was repeated except that (RS)-2-phenylbutyl bromide was used instead of (R)-2-phenylbutyl bromide to give N-α-L-aspartyl-(1R, 2S, 4RS)-1-methyl-2-hydroxy-4-phenylhexylamide as a solid in a total yield of 16.7%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>) δ:0.66(t,1.5H), 0.70(d,1.5H), 0.93 (d,1.5H), 0.97(d,1.5H), 1.40-1.75(m,4H), 2.10-2.65(m,3H), 3.00 (m,0.5H), 3.40(m,0.5H), 3.55-3.90(m,2H), 7.13-7.29(m,5H), 8.07(brd,0.5H), 8.17(brd,0.5H)

ESI-MS 322.8 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 2,300 times

Example 4

5

Synthesis of N- $\alpha$ -L-aspartyl-(1R, 2S, 4RS)-1-methyl-2-hydroxy-4-phenylpentylamide

Example 1 was repeated except that (RS)-2-phenylpropyl bromide was used instead of (R)-2-phenylbutyl bromide to give N- $\alpha$ -L-aspartyl-(1R, 2S, 4RS)-1-methyl-2-hydroxy-4-phenylpentylamide (2S:2R = 7:3) as a solid in a total yield of 29.3%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>) δ:0.94(d,1.5H), 1.00(d,1.5H), 1.16(d,1.5H),

1.18(d,1.5H), 1.46-1.72(m,2H), 2.33-2.60(m,2H), 2.92(m, 0.5H), 3.06(m,0.5H), 3.45-3.83(m,2H), 7.12-

7.38(m,5H) 8.14(d,0.5H), 8.24(d,0.5H)

ESI-MS 309.3 (MH<sup>+</sup>)

15 Degree of sweetness (relative to sugar) 700 times

Example 5Synthesis of N- $\alpha$ -L-aspartyl-(1R, 2S, 4RS)-1-methyl-2-hydroxy-4-phenyl-5-methoxypentylamide

20

Example 1 was repeated except that (RS)-2-phenyl-3-methoxypropyl bromide was used instead of (R)-2-phenylbutyl bromide to give N- $\alpha$ -L-aspartyl-(1R, 2S, 4RS)-1-methyl-2-hydroxy-4-phenyl-5-methoxypentylamide (2S:2R = 7:3) as a solid in a total yield of 34.5%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>) δ:0.93(d,1.5H), 0.98(d,1.5H), 1.46-1.84 (m,2H), 2.68-2.80(m,2H), 2.94-3.22(m,2H), 3.18(s,3H),

25 3.29-3.53(m,2H), 3.53-3.78(m,1H), 3.90-4.00(m,1H), 7.14-7.32(m,5H), 8.30(d,0.5H), 8.39(d,0.5H)

ESI-MS 339.1 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 100 times

Example 6

30

Synthesis of N- $\alpha$ -L-aspartyl-(1R, 2S, 4RS)-1-ethyl-2-hydroxy-4-phenylhexylamide

Example 1 was repeated except that (RS)-2-phenylbutyl bromide was used instead of (R)-2-phenylbutyl bromide and N-methoxy-N-methylcarboxyamide of N,N-dibenzyl- $\alpha$ -D-aminobutyric acid instead of N-methoxy-N-methylcarboxyamide of N,N-dibenzyl- $\alpha$ -D-alanine respectively. Consequently, N- $\alpha$ -L-aspartyl-(1R, 2S, 4RS)-1-ethyl-2-hydroxy-4-phenylhexylamide (2S:2R = >9:1) was obtained as a solid in a total yield of 35.3%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>) δ:0.60-0.84(m,6H), 1.15-1.78(m,6H), 2.33-2.75(m,3H), 2.97(m,1H), 3.45(m,1H), 3.59(m,1H),

3.77 (m,1H), 7.13-7.38(m,5H), 7.95-8.23(brd,1H)

ESI-MS 337.5 (MH<sup>+</sup>)

40 Degree of sweetness (relative to sugar) 250 times

Example 7Synthesis of N- $\alpha$ -L-aspartyl-(1R, 2S, 4RS)-1- $\alpha$ -hydroxyethyl-2-hydroxy-4-phenylhexylamide

45

Example 1 was repeated except that (RS)-2-phenylbutyl bromide was used instead of (R)-2-phenylbutyl bromide and N-methoxy-N-methylcarboxyamide of N,N-dibenzyl-O-benzyl- $\alpha$ -D-threonine instead of N-methoxy-N-methylcarboxyamide of N,N-dibenzyl- $\alpha$ -D-alanine respectively. Consequently, N- $\alpha$ -L-aspartyl-(1R, 2S, 4RS)-1- $\alpha$ -hydroxyethyl-2-hydroxy-4-phenylhexylamide (2S:2R = 9:1) was obtained as a solid in a total yield of 16.7%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>) δ:0.60-0.72(m,3H), 0.82-0.98(m,3H), 1.30-1.84(m,4H), 2.24-2.40(m,2H), 2.50-2.60(m,1H),

50 2.66-2.80 (m,1H), 2.35-3.65(m,1H), 3.65-3.90(m,1H), 4.00-4.40 (m,1H), 7.12-7.34(m,5H), 8.06(brs,1H)

ESI-MS 353.6(MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 100 times

Example 8Synthesis of N- $\alpha$ -L-aspartyl-(1R, 2S)-1-methyl-2-hydroxy-4-phenylbutylamide

Example 1 was repeated except that 2-phenylethyl bromide was used instead of (R)-2-phenylbutyl bromide to give

N- $\alpha$ -L-aspartyl-(1R, 2S)-1-methyl-2-hydroxy-4-phenylbutylamide (2S:2R = 9:1) as a solid in a total yield of 28.5%.

$^1\text{H}\text{NMR}(\text{DMSO-}d_6)$   $\delta$ : 1.00(d,3H), 1.46-1.65(m,1H), 1.65-1.73(m,1H), 2.19(dd,1H), 2.39(dd,1H), 2.55-2.60(m,1H), 2.69-2.80(m,1H), 3.30-3.38(m,1H), 3.58-3.64(m,1H), 3.66-3.74(m,1H)

ESI-MS 295.2 (MH $^+$ )

5 Degree of sweetness (relative to sugar) 50 times

Example 9

Synthesis of N- $\alpha$ -L-aspartyl-(1R, 2R, 4RS)-1-methyl-2-hydroxy-4-phenylhexylamide

10 LAH (0.40 g, 10.5 mmols) was suspended in 20 ml of ether, and the suspension was maintained at 0°C. To this suspension were added 1.63 g (7.0 mmols) of N-methoxy-N-methylcarboxamide of N-tert-butoxycarbonyl- $\alpha$ -D-alanine. The mixture was stirred at 0°C for 1 hour, and 25 ml of a 1-M potassium hydrogensulfate aqueous solution were added thereto. The reaction solution was extracted twice with 50 ml of ether. The organic layer was washed with 50 ml of a 5% sodium hydrogencarbonate aqueous solution and with a saturated aqueous solution of sodium chloride, and was dried over anhydrous magnesium sulfate. Magnesium sulfate was removed by filtration, and the filtrate was concentrated to obtain 1.21 g (7.0 mmols) of (R)-2-N-tert-butoxycarbonylaminopropyl aldehyde as a solid.

15 Magnesium (0.63 g, 26.3 mmols) was suspended in 2 ml of THF, and a solution of 3.73 g (17.5 mmols) of (RS)-2-phenylbutyl bromide in 3 ml of THF was added dropwise to the suspension. The reaction solution was stirred at room temperature for 1 hour, and 5 ml of THF were then added thereto. The mixed solution was cooled to -78°C. To the reaction solution was added a solution obtained by dissolving 1.21 g (7.0 mmols) of the above-obtained (R)-2-N-tert-butoxycarbonylaminopropyl aldehyde in 10 ml of THF. The temperature was gradually elevated from -78°C, and the mixture was then stirred at room temperature for 15 hours. To this reaction solution were added 50 ml of a saturated aqueous solution of ammonium chloride, and the mixture was extracted twice with 50 ml of ether. The organic layer was washed with 5% sodium hydrogencarbonate and with a saturated aqueous solution of sodium chloride, and was dried over anhydrous magnesium sulfate. Magnesium sulfate was removed by filtration, and the filtrate was concentrated. The residue was purified with PTLC to obtain 0.91 g (2.96 mmols) of (1R, 2S, 4RS)-N-tert-butoxycarbonyl-1-methyl-2-hydroxy-4-phenylhexylamine (2S:2R = 3:7) as an oil.

20 Fifteen milliliters of a solution containing 4-N HCl and dioxane were added to 0.91 g (2.96 mmols) of (1R, 2R, 4RS)-N-tert-butoxycarbonyl-1-methyl-2-hydroxy-4-phenylhexylamine, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was further concentrated after the addition of 25 ml of ether. The resulting residue was dissolved in 25 ml of methylene chloride. The reaction solution was cooled to 0°C, and 1.17 g (3.26 mmols) of N-benzyloxycarbonyl-L-aspartic acid- $\beta$ -benzyl ester, 0.45 ml (3.26 mmols) of triethylamine, 0.63 g (3.26 mmols) of water-soluble carbodiimide and 0.44 g (3.26 mmols) of HOBr were added thereto. The reaction solution was stirred for 1 hour while being cooled and then overnight at room temperature. After the reaction solution was concentrated under reduced pressure, 50 ml of water were added to the residue, and the resulting solution was extracted twice with 50 ml of ethyl acetate. The organic layer was washed twice with 50 ml of a 5% citric acid aqueous solution, with 50 ml of water, with 50 ml of a 5% sodium hydrogencarbonate aqueous solution and with 50 ml of a saturated aqueous solution of sodium chloride. The organic layer was dried over anhydrous magnesium sulfate, and magnesium sulfate was then removed by filtration. The filtrate was concentrated under reduced pressure, and was purified with PTCL to obtain 1.15 g (2.11 mmols) of N- $\alpha$ -L-(N'-benzyloxycarbonyl- $\beta$ -O-benzylaspartyl)-(1R, 2R, 4RS)-1-methyl-2-hydroxy-4-phenylhexylamide as a viscous oil.

25 N- $\alpha$ -L-(N'-benzyloxycarbonyl- $\beta$ -O-benzylaspartyl)-(1R, 2R, 4RS)-1-methyl-2-hydroxy-4-phenylhexylamide (1.15 g, 2.11 mmols) was dissolved in 35 ml of methanol, and 5 ml of water and 0.35 g of 5% palladium on carbon (water content 50%) were added thereto. The mixed solution was reduced under a hydrogen atmosphere overnight at room temperature. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was then dried to give 0.59 g (1.84 mmols) of N- $\alpha$ -L-aspartyl-(1R, 2R, 4RS)-1-methyl-2-hydroxy-4-phenylhexylamide (2S:2R = 3:7) as a solid.

30  $^1\text{H}\text{NMR}(\text{DMSO-}d_6)$   $\delta$ : 0.67(t,1.5H), 0.69(t,1.5H), 0.91(d,1.5H)

0.96(d,1.5H), 1.40-1.75(m,4H), 2.40-2.70(m,3H), 2.95-3.90  
(m,3H), 7.10-7.35(m,5H), 8.07(brs,1H)

35 ESI-MS 323.1 (MH $^+$ )

Degree of sweetness (relative to sugar) 1,000 times

40 55 Example 10

Synthesis of N- $\alpha$ -L-aspartyl-(1R, 2R, 4R)-1-methyl-2-hydroxy-4-phenylhexylamide

Example 9 was repeated except that (S)-2-phenylbutyl bromide was used instead of (RS)-2-phenylbutyl bromide to

give N- $\alpha$ -L-aspartyl-(1R, 2R, 4R)-1-methyl-2-hydroxy-4-phenylhexylamide (2S:2R = 3:7) as a solid in a total yield of 38.6%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>)  $\delta$ : 0.58-0.73(m,3H), 0.88-1.00(m,3H), 1.35-1.75(m,4H), 2.45-2.75(m,3H), 3.05-3.95(m,3H), 7.13-7.32(m,5H), 8.07(d,1H)

5 ESI-MS 323.1 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 800 times

Example 11

10 Synthesis of N- $\alpha$ -L-aspartyl-(2RS, 4RS)-1,1-dimethyl-2-hydroxy-4-phenylhexylamide

Example 9 was repeated except that N-methoxy-N-methylcarboxamide of N-tert-butoxycarbonyl- $\alpha$ , $\alpha$ -dimethylglycine was used instead of N-methoxy-N-methylcarboxamide of N-tert-butoxycarbonyl- $\alpha$ -D-alanine to give N- $\alpha$ -aspartyl-(2RS, 4RS)-1,1-dimethyl-2-hydroxy-4-phenylhexylamide as a solid in a total yield of 8.3%.

15 <sup>1</sup>HNMR(DMSO-d<sub>6</sub>)  $\delta$ : 0.64-0.75(m,3H), 1.05-1.25(m,6H), 1.25-1.90(m,4H), 2.10-2.50(m,2H), 2.58(m,1H), 3.05(m,1H),

3.45-3.90(m,2H), 7.13-7.30(m,5H), 7.93(brs,0.5H), 8.07 (brd,0.5H)

ESI-MS 337.6 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 250 times

20

Example 12

Synthesis of N- $\alpha$ -L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide

25 N-tert-butoxycarbonyl-L-aspartic acid- $\beta$ -benzyl ester (0.91 g, 2.80 mmols) and 0.58 g (2.80 mmols) of (1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamine (0.58 g, 2.80 mmols) which had been formed as in Example 1 were added to 30 ml of methylene chloride. The reaction solution was cooled to 0°C, and 0.59 g (3.08 mmols) of water-soluble carbodiimide hydrochloride and 0.42 g (3.08 mmols) of HOBt were added thereto. The mixed solution was stirred for 1 hour while being cooled and then overnight at room temperature. After the reaction mixture was concentrated under reduced pressure, 50 ml of water were added to the residue, and the mixture was extracted twice with 50 ml of ethyl acetate. The organic layer was washed twice with a 5%-citric acid aqueous solution, with 50 ml of water, twice with a 5%-sodium hydrogencarbonate aqueous solution and with 50 ml of a saturated aqueous solution of sodium chloride. After the organic layer was dried over anhydrous magnesium sulfate, magnesium sulfate was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain 1.43 g (2.78 mmols) of N- $\alpha$ -L-(N'-tert-butoxycarbonyl- $\beta$ -O-benzylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide as a viscous oil.

30 Seven milliliters of a solution containing 4-N HCl and dioxane were added to 1.43 g (2.78 mmols) of N- $\alpha$ -L-(N'-tert-butoxycarbonyl- $\beta$ -O-benzylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and 50 ml of a 5%-sodium hydrogencarbonate aqueous solution were added to the residue. The mixture was extracted twice with 50 ml of ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium chloride, and was dried over anhydrous magnesium sulfate. Magnesium sulfate was then removed by filtration, and the filtrate was concentrated under reduced pressure to obtain 1.13 g (2.73 mmols) of N- $\alpha$ -L-( $\beta$ -O-benzylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide as a pale yellow oil.

35 N- $\alpha$ -L-( $\beta$ -O-benzylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide (1.13 g, 2.73 mmols) was suspended in 20 ml of THF, and the suspension was maintained at 0°C. To this suspension were added 0.16 ml (2.73 mmols) of acetic acid, 0.34 ml (2.73 mmols) of 3,3-dimethylbutyl aldehyde and 0.87 g (4.10 mmols) of NaB(OAc)<sub>3</sub>H. The mixture was stirred at 0°C for 1 hour and then overnight at room temperature. To the reaction solution were added 30 ml of a saturated aqueous solution of sodium hydrogencarbonate, and the mixture was extracted twice with 50 ml of ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium chloride, and was dried over anhydrous magnesium sulfate. Magnesium sulfate was then removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified with PTLC to obtain 1.04 g (2.09 mmols) of N- $\alpha$ -L-(N'-3,3-dimethylbutyl- $\beta$ -O-benzylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide as a pale yellow oil.

40 N- $\alpha$ -L-(N'-3,3-dimethylbutyl- $\beta$ -O-benzylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide (1.04 g, 2.09 mmols) was dissolved in 40 ml of methanol, and 5 ml of water and 0.50 g of 5%-palladium on carbon (water content 50%) were added thereto. The solution was reduced under a hydrogen atmosphere overnight at room temperature. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was then dried to give 0.74 g (1.81 mmols) of N- $\alpha$ -L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide (2S:2R = >5:1) as a solid.

45 <sup>1</sup>HNMR(DMSO-d<sub>6</sub>)  $\delta$ : 0.66(t,3H), 0.83(s,9H), 1.00(d,3H), 1.35-1.56(m,4H), 1.63-1.76(m,2H), 2.55-2.72(m,5H),

3.40-3.48(m,1H), 3.75-3.88(m,2H), 4.70(brs,1H), 7.10-7.30(m,5H), 8.34(d,1H)  
 ESI-MS 407.4 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 5,500 times

5 Example 13

Synthesis of N- $\alpha$ -L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2S, 4R)-1-methyl-2-hydroxy-4-phenylhexylamide

Example 12 was repeated except that (S)-2-phenylbutyl bromide was used instead of (R)-2-phenylbutyl bromide to give N- $\alpha$ -L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2S, 4R)-1-methyl-2-hydroxy-4-phenylhexylamide (2S:2R = >9:1) as a solid in a total yield of 52.2%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>)  $\delta$ : 0.69(t,3H), 0.85(s,9H), 0.93(d,3H), 1.38-1.66(m,6H), 2.60-2.78(m,5H), 3.00-3.10(m,1H), 3.58-3.67(m,1H), 3.81(t,1H), 7.10-7.30(m,5H), 4.60 (brs,1H), 8.26(d,1H)

ESI-MS 407.4 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 3,000 times

Example 14

Synthesis of N- $\alpha$ -L-(N'-2-ethylbutylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide

Example 12 was repeated except that 2-ethylbutyl aldehyde was used instead of 3,3-dimethylbutyl aldehyde to give N- $\alpha$ -L-(N'-2-ethylbutylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide as a solid in a total yield of 30.6%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>)  $\delta$ : 0.66(t,3H), 0.79(t,6H), 1.00(d,3H), 1.22-1.36(m,4H), 1.36-1.54(m,3H), 1.64-1.77(m,2H), 2.50-2.66(m,5H), 3.38(brs,1H), 3.67(t,1H), 3.73-3.83 (m,1H), 4.66(brs,1H), 7.10-7.23(m,5H), 8.17(d,1H)

ESI-MS 407.4 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 3,000 times

Example 15

Synthesis of N- $\alpha$ -L-(N'-3-methylbutylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide

Example 12 was repeated except that 3-methylbutyl aldehyde was used instead of 3,3-dimethylbutyl aldehyde to give N- $\alpha$ -L-(N'-3-ethylbutylaspartyl)-(1R, 2S, 4S)-1-methyl-2-hydroxy-4-phenylhexylamide as a solid in a total yield of 25.4%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>)  $\delta$ : 0.66(t,3H), 0.83(d,3H), 0.84(d,3H), 1.00(d,3H), 1.30-1.62(m,5H), 1.62-1.76(m,2H), 2.40-2.54(m,3H), 2.60(t,2H), 3.34-3.44(m,1H), 3.64(t,1H), 3.70-3.80(m,1H), 4.67(brs,1H), 7.12-7.32(m,5H), 8.14(d,1H)

ESI-MS 393.4 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 4,000 times

Example 16

Synthesis of N- $\alpha$ -L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2S)-1-methyl-2-hydroxy-3-cyclohexylpropylamide

Example 12 was repeated except that cyclohexylmethyl bromide was used instead of (R)-2-phenylbutyl bromide to give N- $\alpha$ -L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2S)-1-methyl-2-hydroxy-3-cyclohexylpropylamide as a solid in a total yield of 11.3%.

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>)  $\delta$ : 0.88(s,9H), 0.99(d,3H), 0.80-1.80 (m,15H), 2.60(d,2H), 2.69(t,2H), 3.41-3.48(m,1H), 3.62-3.72(m,1H), 3.77(t,1H), 4.57(brs,1H), 8.25(d,1H)

ESI-MS 371.4 (MH<sup>+</sup>)

Degree of sweetness (relative to sugar) 100 times

Example 17

Synthesis of N- $\alpha$ -L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2R)-1-methyl-2-hydroxy-3-cyclohexylpropylamide

LAH (0.66 g, 17.5 mmols) was suspended in 40 ml of ether, and the suspension was maintained at 0°C. To this suspension were added 2.32 g (10.0 mmols) of N-methoxy-N-methylcarboxamide of N-tert-butoxycarbonyl- $\alpha$ -D-alanine. The mixture was stirred at 0°C for 1 hour, and 25 ml of a 1-M potassium hydrogensulfate aqueous solution were then

added thereto. The reaction solution was extracted twice with 50 ml of ether. The organic layer was washed with 50 ml of a 5% sodium hydrogencarbonate aqueous solution and with a saturated aqueous solution of sodium chloride, and was dried over anhydrous magnesium sulfate. Magnesium sulfate was removed by filtration, and the filtrate was concentrated to obtain 1.29 g (7.43 mmols) of (R)-2-N-tert-butoxycarbonylaminopropyl aldehyde as a solid.

5      Magnesium (0.68 g, 27.8 mmols) was suspended in 2 ml of THF, and a solution of 3.29 g (18.6 mmols) of cyclohexylmethyl bromide in 3 ml of THF was added dropwise to the suspension. The reaction solution was stirred at room temperature for 1 hour, and 5 ml of THF were added thereto. The mixed solution was cooled to -78°C. To the reaction solution was added a solution obtained by dissolving 1.29 g (7.43 mmols) of the above-obtained (R)-2-N-tert-butoxycarbonylaminopropyl aldehyde in 10 ml of THF. The temperature was gradually elevated from -78°C, and the mixture was  
10     then stirred at room temperature for 15 hours. To this reaction solution were added 50 ml of a saturated aqueous solution of ammonium chloride, and the mixture was extracted twice with 50 ml of ether. The organic layer was washed with 5% sodium hydrogencarbonate and with a saturated aqueous solution of sodium chloride, and was dried over anhydrous magnesium sulfate. Magnesium sulfate was removed by filtration, and the filtrate was concentrated. The residue was purified with PTLC to obtain 0.88 g (3.25 mmols) of (1R, 2R)-N-tert-butoxycarbonyl-1-methyl-2-hydroxy-3-cyclohexylpropylamine (2S:2R = 3:7) as an oil.

15     Fifteen milliliters of a solution containing 4-N HCl and dioxane were added to 0.88 g (3.25 mmols) of (1R, 2R)-N-tert-butoxycarbonyl-1-methyl-2-hydroxypropylamine, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was further concentrated after the addition of 25 ml of ether. The resulting residue was dissolved in 30 ml of methylene chloride, and the solution was cooled to 20     0°C. N-tert-butoxycarbonyl-L-aspartic acid-β -benzyl ester 1.11 g (3.42 mmols), 0.50 ml (3.58 mmols) of triethylamine, 0.69 g (3.58 mmols) of water-soluble carbodiimide and 0.48 g (3.58 mmols) of HOBt were added to the above-obtained solution. The mixture was stirred for 1 hour while being cooled and then overnight at room temperature. After the reaction solution was concentrated under reduced pressure, 50 ml of water were added to the residue, and the mixture was extracted twice with 50 ml of ethyl acetate. The organic layer was washed twice with 50 ml of a 5% citric acid aqueous solution, with 50 ml of water, twice with a 5% sodium hydrogencarbonate aqueous solution and with 50 ml of a saturated aqueous solution of sodium chloride. The organic layer was dried over anhydrous magnesium sulfate, and magnesium sulfate was then removed by filtration. The filtrate was concentrated under reduced pressure, and was purified through PTLC to obtain 0.81 g (1.69 mmols) of N-α-L-(N'-tert-butoxycarbonyl-β-O-benzylaspartyl)-(1R, 2R)-1-methyl-2-hydroxy-3-cyclohexylpropylamide as a viscous oil.

25     Eight milliliters of a solution containing 4-N HCl and dioxane were added to 0.81 g (1.69 mmols) of N-α-L-(N'-tert-butoxycarbonyl-β-O-benzylaspartyl)-(1R, 2R)-1-methyl-2-hydroxy-3-cyclohexylpropylamide, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and 50 ml of a 5% sodium hydrogencarbonate aqueous solution were added to the residue. The mixture was extracted twice with 50 ml of ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium chloride, and was dried over anhydrous magnesium sulfate. Magnesium sulfate was then removed by filtration, and the filtrate was concentrated under reduced pressure to obtain 0.60 g (1.60 mmols) of N-α-L-(β-O-benzylaspartyl)-(1R, 2R)-1-methyl-2-hydroxy-3-cyclohexylpropylamide as a pale yellow viscous oil.

30     N-α-L-(β-O-benzylaspartyl)-(1R, 2R)-1-methyl-2-hydroxy-3-cyclohexylpropylamide (0.60 g, 1.60 mmols) was suspended in 12 ml of THF, and the suspension was maintained at 0°C. To this suspension were added 0.092 ml (1.60 mmols) of acetic acid, 0.20 ml (1.60 mmols) of 3,3-dimethylbutyl aldehyde and 0.51 g (2.41 mmols) of NaB(OAc)<sub>3</sub>H. The mixture was stirred at 0°C for 1 hour and then overnight at room temperature. Twenty milliliters of a saturated aqueous solution of sodium hydrogencarbonate were added to the reaction solution, and the mixture was extracted twice with 50 ml of ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium chloride, and was dried over anhydrous magnesium sulfate. Magnesium sulfate was then removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified with PTLC to obtain 0.50 g (1.09 mmols) of N-α-L-(N'-3,3-dimethylbutyl-β-O-benzylaspartyl)-(1R, 2R)-1-methyl-2-hydroxy-3-cyclohexylpropylamide as a pale yellow oil.

35     N-α-L-(N'-3,3-dimethylbutyl-β-O-benzylaspartyl)-(1R, 2R)-1-methyl-2-hydroxy-3-cyclohexylpropylamide (0.50 g, 1.09 mmols) was dissolved in 30 ml of methanol, and 5 ml of water and 0.25 g of 5% palladium on carbon (water content 50%) were added thereto. The solution was reduced under a hydrogen atmosphere at room temperature for 4 hours. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was then dried to give 0.36 g (0.98 mmols) of N-α-L-(N'-3,3-dimethylbutylaspartyl)-(1R, 2R)-1-methyl-2-hydroxy-3-cyclohexylpropylamide as a solid.

40     <sup>1</sup>HNMR(DMSO-d<sub>6</sub>) δ: 0.86(s,9H), 1.02(d,3H), 0.80-1.74(m,15H),


45     2.48-2.56(m,2H), 2.60-2.70(m,2H), 3.40-3.55(m,1H), 3.63-3.83(m,2H), 4.53(brs,1H), 8.06(d,1H)

50     ESI-MS 371.4 (MH<sup>+</sup>)

55     Degree of sweetness (relative to sugar) 750 times

## Claims

## 1. Aspartylamide derivatives represented by formula (I)




wherein

10  $R_1$  represents H, a saturated or unsaturated linear or cyclic hydrocarbon group having from 1 to 13 carbon atoms, or a mixed hydrocarbon group thereof;

15  $R^2$  and  $R^3$  each represent H, or a substituent selected from an alkyl group having from 1 to 6 carbon atoms, an alkoxyalkyl group having from 2 to 7 carbon atoms, a hydroxyalkyl group having from 2 to 7 carbon atoms, a phenyl group, a 2-furyl group, a dimethylene group, a trimethylene group, a tetramethylene group and a pentamethylene group;

20 when  $R_1$  is a saturated or unsaturated linear or cyclic hydrocarbon group having from 1 to 13 carbon atoms or a mixed hydrocarbon group thereof,  $R_4$  represents an alkyl group having from 1 to 12 carbon atoms, or a substituent represented by formula (II) or (III), and when  $R_1$  is H,  $R_4$  represents a substituent represented by formula (III)



in which

25 in formula (II)

$R_5$  represents H, or an alkyl group having from 1 to 4 carbon atoms,

30  $R_6$  represents a 3- to 10-membered cycloalkyl group having a total of 12 or less carbon atoms, a cycloalkenyl group, a cycloalkyl group which is substituted by an alkyl group, a cycloalkenyl group, a bicycloalkyl group, a bicycloalkenyl group, or a tricycloalkenyl group, and

35  $n$  represents 0 or 1, and

in formula (III)

40  $R_7$  and  $R_8$  each represent H, a cycloalkyl group having from 3 to 4 carbon atoms, an alkyl group having from 1 to 6 carbon atoms, an alkoxyalkyl group having from 2 to 7 carbon atoms, a phenyl group, a phenyl group having a substituent selected from F, Cl, Br, I, a hydroxy group, an alkyl group having from 1 to 6 carbon atoms, an alkoxy group having from 2 to 7 carbon atoms, a cyano group, a nitro group, an acetyl group, an amino group and an acetyl amino group in the 2-, 3- or 4-position, a phenyl group having a methylenedioxy group, a trimethylene group or a tetramethylene group in the 2-and 3-positions or in the 3- and 4-positions, a 2-, 3- or 4-pyridyl group, a 2- or 3-furyl group, or a 2- or 3-thienyl group, and

45  $m$  represents 0 or 1; and

the  $C^1$ -configuration is (S), and the  $C^2$ -,  $C^3$ - and  $C^4$ -configurations are (R), (S) or (RS),

and salts thereof.

2. The compounds of claim 1, wherein  $R_1$  is H,  $R_2$  is H,  $R_3$  is a methyl group,  $R_4$  is a (S)-, (R)- or (RS)-2-phenylbutyl group, the  $C^2$ -configuration is (R), and the  $C^3$ -configuration is (S), (R) or (RS).

3. The compounds of claim 1, wherein  $R_1$  is H,  $R_2$  is H,  $R_3$  is a methyl group,  $R_4$  is a (S)-, (R)- or (RS)-2-phenylpropyl group, the  $C^2$ -configuration is (R), and the  $C^3$ -configuration is (S), (R) or (RS).

4. The compounds of claim 1, wherein  $R_1$  is H,  $R_2$  is H,  $R_3$  is a methyl group,  $R_4$  is a (S)-, (R)- or (RS)-2-phenyl-3-methoxypropyl group, the  $C^2$ -configuration is (R), and the  $C^3$ -configuration is (S), (R) or (RS).

5. The compounds of claim 1, wherein  $R_1$  is H,  $R_2$  is H,  $R_3$  is an ethyl group,  $R_4$  is a (S)-, (R)- or (RS)-2-phenylbutyl group, the  $C^2$ -configuration is (R), and the  $C^3$ -configuration is (S), (R) or (RS).

6. The compounds of claim 1, wherein  $R_1$  is H,  $R_2$  is H,  $R_3$  is a 1-hydroxyethyl group,  $R_4$  is a (S)-, (R)- or (RS)-2-phenylbutyl group, the  $C^2$ -configuration is (R), and the  $C^3$ -configuration is (S), (R) or (RS).

7. The compounds of claim 1, wherein  $R_1$  is H,  $R_2$  and  $R_3$  are methyl groups,  $R_4$  is a (S)-, (R)- or (RS)-2-phenylbutyl

group, and the C<sup>3</sup>-configuration is (S), (R) or (RS).

8. The compounds of claim 1, wherein R<sub>1</sub> is H, R<sub>2</sub> is H, R<sub>3</sub> is a methyl group, R<sub>4</sub> is a 2-phenylethyl group, the C<sup>2</sup>-configuration is (R), and the C<sup>3</sup>-configuration is (S), (R) or (RS).
- 5 9. The compounds of claim 1, wherein R<sub>1</sub> is a 3,3-dimethylbutyl group, R<sub>2</sub> is H, R<sub>3</sub> is a methyl group, R<sub>4</sub> is a (S)-, (R)- or (RS)-2-phenylbutyl group, the C<sup>2</sup>-configuration is (R), and the C<sup>3</sup>-configuration is (S), (R) or (RS).
10. The compounds of claim 1, wherein R<sub>1</sub> is a 2-ethylbutyl group, R<sub>2</sub> is H, R<sub>3</sub> is a methyl group, R<sub>4</sub> is a (S)-, (R)- or (RS)-2-phenylbutyl group, the C<sup>2</sup>-configuration is (R), and the C<sup>3</sup>-configuration is (S), (R) or (RS).
11. The compounds of claim 1, wherein R<sub>1</sub> is a 3-methylbutyl group, R<sub>2</sub> is H, R<sub>3</sub> is a methyl group, R<sub>4</sub> is a (S)-, (R)- or (RS)-2-phenylbutyl group, the C<sup>2</sup>-configuration is (R), and the C<sup>3</sup>-configuration is (S), (R) or (RS).
- 15 12. The compounds of claim 1, wherein R<sub>1</sub> is a 3,3-dimethylbutyl group, R<sub>2</sub> is H, R<sub>3</sub> is a methyl group, R<sub>4</sub> is a cyclohexylmethyl group, the C<sup>2</sup>-configuration is (R), and the C<sup>3</sup>-configuration is (S), (R) or (RS).
13. A sweetener containing the novel aspartylamide derivatives of formula (I) or salts thereof as an active ingredient.

20

25

30

35

40

45

50

55



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 96 12 0524

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	C07C237/08 A23L1/236
X, D	J. MED. CHEM. (1970), 13(6), 1217-21 CODEN: JMCMAR, 1970, XP000647938 MAZUR, ROBERT H. ET AL: "Structure-taste relation of aspartic acid amides" * example 15 *	1,13	C07C237/08 A23L1/236
X, D	TETRAHEDRON LETT. (1994), 35(37), 6891-4 CODEN: TELEAY; ISSN: 0040-4039, 1994, XP000647937 YUASA, YOSHIFUMI ET AL: "The sweetness and stereochemistry of L-aspartyl-fenchylaminoalcohol derivatives" * example 3 *	1,13	C07C237/08 A23L1/236
X, D	EP 0 203 540 A (GEN FOODS CORP) 3 December 1986 * claim 1; examples *	1,13	C07C237/08 A23L1/236
X	US 3 803 223 A (GOLDKAMP A ET AL) 9 April 1974 * column 1; example 3 *	1,13	C07C237/08 A23L1/236
X	DE 19 06 048 A (G.D.SEARLE & CO) 28 August 1969 * page 7 - page 12; claims *	1,13	C07C237/08 A23L1/236
X	EP 0 255 343 A (TAKASAGO PERFUMERY CO LTD) 3 February 1988 * the whole document *	1,13	C07C237/08 A23L1/236
X	EP 0 310 341 A (TAKASAGO PERFUMERY CO LTD) 5 April 1989 * page 1-3 *	1,13	C07C237/08 A23L1/236
		-/-	C07C237/08 A23L1/236
The present search report has been drawn up for all claims			C07C237/08 A23L1/236
Place of search		Date of completion of the search	Examiner
THE HAGUE		25 April 1997	Sánchez García, J.M.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons G : member of the same patent family, corresponding document			



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 96 12 0524

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.)						
A,D	US 4 423 029 A (RIZZI GEORGE P) 27 December 1983 * claims *	1-13 -----							
TECHNICAL FIELDS SEARCHED (Int.Cl.)									
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 33%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>25 April 1997</td> <td>Sánchez García, J.M.</td> </tr> </table> <p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons  &amp; : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	THE HAGUE	25 April 1997	Sánchez García, J.M.
Place of search	Date of completion of the search	Examiner							
THE HAGUE	25 April 1997	Sánchez García, J.M.							